Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial of a PARP inhibitor called AG014699 and temozolomide for advanced cancer
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial was looking at a combination of AG014699 and temozolomide for advanced cancer. This trial was supported by Cancer Research UK.
Doctors often treat
PARP is an
This trial was looking at a treatment called a PARP inhibitor, which blocks PARP. The PARP inhibitor they used was called AG014699. They were testing it in combination with a chemotherapy drug called temozolomide.
The trial was in 2 parts. The first part was for people with different types of
The main aims of the trial were to
- Find the best doses of temozolomide and AG014699 to have together
- Learn more about how AG014699 worked and what the side effects were
- See how well the combination of temozolomide and AG014699 worked
Summary of results
The trial team worked out safe doses of AG014699 and temozolomide that could be used together. And they found that cancer responded to this drug combination in about 1 in 10 people (10%) in this trial.
In the first part of the trial, the people taking part had a range of solid tumours. Everybody had a low dose of temozolomide. The first few people also had a low dose of AG014699. As they didn’t have any serious side effects, the next few people had a higher dose of AG014699 and so on. In this way, the researchers found the highest dose of AG014699 that they could give safely with temozolomide.
In the second part of the trial, the people taking part all had melanoma. Everybody had the highest safe dose of AG014699 that had been worked out in part 1. This time, the researchers slowly increased the dose of temozolomide. By doing this, they found the highest doses of both drugs that could be used together, without causing too many side effects.
- 32 people had treatment as part of this trial
- In 1 person who had melanoma, the cancer disappeared completely – researchers call this a
complete response. And after more than a year and a half, it had not started growing again
- In 2 people, the cancer had got smaller – researchers call this a
- In 10 people, the cancer had stayed the same size – researchers call this
- In 16 people, the cancer had got bigger
- The researchers didn’t have results for 3 people
The trial team learnt more about how AG014699 worked, and found that having the 2 drugs together helped some people in this trial. They suggest this should be looked at in further clinical trials involving more people.
We have based this summary on information from the team who ran the trial. As far as we are aware, the information they sent us has not been reviewed independently (
How to join a clinical trial
Professor H Calvert
Cancer Research UK (Centre for Drug Development)
This is Cancer Research UK trial number CRUKD/03/042.